Literature DB >> 6819251

Neurophysiological studies in GM1, gangliosidosis.

A Harden, Z Martinovic, G Pampiglione.   

Abstract

Neurophysiological studies (EEG, ERG, VEP) have been carried out on 8 children with proven GM1 gangliosidosis (3 of Type I and 5 of Type II). All the EEGs were abnormal showing an increasing amount of irregular slow activity as the disease progressed. Around 2 to 3 years of age, Type II patients often showed a fluctuating 4-5 c/s rhythmic activity especially prominent in the temporal regions. Paroxysmal activity was not a conspicuous feature in any of the patients. The ERG was normal in all cases but the VEP was variably altered. The EEG/ERG/VEP findings in GM1 gangliosidosis differ from those seen in most other neurometabolic disorders of childhood.

Entities:  

Mesh:

Year:  1982        PMID: 6819251     DOI: 10.1007/bf02043310

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  14 in total

1.  Development of rhythmic E.E.G. activities in infancy (waking state).

Authors:  G Pampiglione
Journal:  Rev Electroencephalogr Neurophysiol Clin       Date:  1977 Jul-Sep

2.  So-called neuronal ceroid lipofuscinosis. Neurophysiological studies in 60 children.

Authors:  G Pampiglione; A Harden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-04       Impact factor: 10.154

3.  GM1-gangliosidosis without chondrodystrophy or visceromegaly. B-galactosidase deficiency with gangliosidosis and the excessive excretion of a keratan sulfate.

Authors:  L S Wolfe; J Callahan; J S Fawcett; F Andermann; C R Scriver
Journal:  Neurology       Date:  1970-01       Impact factor: 9.910

4.  Late infantile systemic lipidosis. Major monosialogangliosidosis. Delineation of two types.

Authors:  D M Derry; J S Fawcett; F Andermann; L S Wolfe
Journal:  Neurology       Date:  1968-04       Impact factor: 9.910

5.  Tay-Sachs disease: neurophysiological studies in 20 children.

Authors:  G Pampiglione; G Privett; A Harden
Journal:  Dev Med Child Neurol       Date:  1974-04       Impact factor: 5.449

6.  GM1 gangliosidosis type II.

Authors:  C Hooft; R F Vlietinck; G Dacremont; J A Kint
Journal:  Eur Neurol       Date:  1970       Impact factor: 1.710

7.  The Gm1 gangliosidosis (Landing disease).

Authors:  C Hooft; L Senesael; M J Delbeke; J Kint; G Dacremont
Journal:  Eur Neurol       Date:  1969       Impact factor: 1.710

8.  E.E.G. studies in 22 children with sulphatide lipidosis (metachromatic leucodystrophy).

Authors:  C Mastropaolo; G Pampiglione; R Stephens
Journal:  Dev Med Child Neurol       Date:  1971-02       Impact factor: 5.449

Review 9.  Ganglioside storage diseases: an updated review.

Authors:  J S O'Brien
Journal:  Ital J Neurol Sci       Date:  1981-08

10.  Generalized gangliosidosis: acid beta-galactosidase deficiency with early onset, rapid mental deterioration and minimal bone dysplasia.

Authors:  H Fricker; J S O'Brien; F Vassella; E Gugler; J P Mühlethaler; M Spycher; U N Wiesmann; N Herschkowitz
Journal:  J Neurol       Date:  1976-10-04       Impact factor: 4.849

View more
  1 in total

1.  Novel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model.

Authors:  Heather L Gray-Edwards; Debra S Regier; Jamie L Shirley; Ashley N Randle; Nouha Salibi; Sarah E Thomas; Yvonne L Latour; Jean Johnston; Gretchen Golas; Annie S Maguire; Amanda R Taylor; Donald C Sorjonen; Victoria J McCurdy; Peter W Christopherson; Allison M Bradbury; Ronald J Beyers; Aime K Johnson; Brandon L Brunson; Nancy R Cox; Henry J Baker; Thomas S Denney; Miguel Sena-Esteves; Cynthia J Tifft; Douglas R Martin
Journal:  Mol Ther       Date:  2017-02-22       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.